Benefits and Risks of Drug Treatments
Authors:
- Jan P. VandenbrouckeJVJan P. Vandenbroucke
- Bruce M. PsatyBPBruce M. Psaty
- 26 November 2008
- journal article
- editorial
- Published by American Medical Association (AMA) in JAMA
- Vol. 300 (20) , 2417-2419
Abstract
The central theme of the Institute of Medicine report on the US drug safety system was the need for a life cycle approach to drug evaluation: both the benefitsKeywords
This publication has 10 references indexed in Scilit:
- Reporting of adverse events in systematic reviews can be improved: survey resultsJournal of Clinical Epidemiology, 2008
- Meta‐analysis: gastrointestinal bleeding due to interaction between selective serotonin uptake inhibitors and non‐steroidal anti‐inflammatory drugsAlimentary Pharmacology & Therapeutics, 2007
- Increasing Levels of Restriction in Pharmacoepidemiologic Database Studies of Elderly and Comparison With Randomized Trial ResultsMedical Care, 2007
- What is the best evidence for determining harms of medical treatment?Canadian Medical Association Journal, 2006
- Comparison of evidence on harms of medical interventions in randomized and nonrandomized studiesCanadian Medical Association Journal, 2006
- Challenges in Systematic Reviews That Assess Treatment HarmsAnnals of Internal Medicine, 2005
- When are observational studies as credible as randomised trials?The Lancet, 2004
- A comparison of three different sources of data in assessing the frequencies of adverse reactions to amiodaroneBritish Journal of Clinical Pharmacology, 2004
- Assessment and Control for Confounding by Indication in Observational StudiesJournal of the American Geriatrics Society, 1999
- CASE-CONTROL STUDIES IN THE EVALUATION OF DRUG-INDUCED ILLNESSAmerican Journal of Epidemiology, 1978